Priority Review for Xifaxan sNDA

FDA accepted for filing and granted Priority Review to an sNDA from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) for Xifaxan rifaximin 550 mg tablets to treat non-constipation irritable bowel syndrome (IBS) and IBS-related bloating. The PDUFA date is Dec. 7. ...